American Journal of Obstetrics and Gynecology
ResearchObstetricsUse of topiramate in pregnancy and risk of oral clefts
Section snippets
Data sources and study populations
The Boston University Slone Epidemiology Center Birth Defects Study (BDS) and the Centers for Disease Control and Prevention's (CDC) National Birth Defects Prevention Study (NBDPS) share several features related to study design, data collection, case classification, and analyses, which have been described in detail elsewhere.20, 21, 22, 23, 24 Both studies include infants with major congenital malformations as cases and infants with no malformations as controls. Prepregnancy and pregnancy
Slone Birth Defects Study
The study population consisted of 6983 controls and 10,618 infants with major congenital malformations (the latter excluded 2594 infants with chromosomal abnormalities, single-gene inherited diseases, malformations associated with amniotic bands, syndromic or metabolic disorders). Among the infants with malformations, 785 had CL/P. Maternal and offspring characteristics of CL/P cases and controls are presented in Table 1. Five infants with malformations were exposed to topiramate monotherapy,
Comment
Monotherapy topiramate use during the first trimester of pregnancy was associated with an increased risk of CL/P as compared with no use of antiepileptics in pooled data from the BDS and NBDPS.
Topiramate has effects on multiple physiological pathways. It affects cell polarization through effects on various ion channels; it also inhibits the carbonic anhydrase12, 26 and histone deacetylases; histone deacetylases are also inhibited by valproic acid.27 Litters born to pregnant rodents exposed to
Acknowledgments
Coding of drug information in the NBDPS used the Slone Drug Dictionary under license from the Slone Epidemiology Center at Boston University. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. We thank the health care providers, project coordinators, medical records reviewers, interviewers, research assistants, programmers in all study centers and participating
References (41)
- et al.
Use of antiepileptic medications in pregnancy in relation to risks of birth defects
Ann Epidemiol
(2011) Treatment options for parasomnias
Neurol Clin
(2010)- et al.
The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies
Reprod Toxicol
(2008) - et al.
Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008
Am J Obstet Gynecol
(2011) - et al.
Cleft lip and palate
Lancet
(2009) - et al.
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry
Lancet Neurol
(2011) Birth defects after prenatal exposure to antiepileptic drugs
Lancet Neurol
(2005)- et al.
Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society
Neurology
(2009) - et al.
The management of epilepsy in pregnancy
BJOG
(2009) - et al.
The teratogenicity of anticonvulsant drugs
N Engl J Med
(2001)
Neural tube defects in relation to use of folic acid antagonists during pregnancy
Am J Epidemiol
Changing patterns of antiepileptic drug use in pregnant Australian women
Acta Neurol Scand
Newer-generation antiepileptic drugs and the risk of major birth defects
JAMA
Topiramate use in women of childbearing age from the U.S. National Health and Human Nutrition Examination Survey (NHANES) (abstract)
Pharmacoepidemiol Drug Safety
Commentary: triptan use during pregnancy: a safe choice?
Headache
Best practice guide for the treatment of nightmare disorder in adults
J Clin Sleep Med
Topiramate for binge-eating disorder associated with obesity
Ann Pharmacother
Pharmacological interventions for borderline personality disorder
Cochrane Database Syst Rev
Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder
J Clin Psychiatry
Full prescribing information for Topamax
Cited by (125)
Medical Malpractice and the Neurologist: Specific Neurological Claims
2023, Neurologic ClinicsAGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
2022, GastroenterologyCitation Excerpt :Due to concerns for arrhythmias and seizures, medications with phentermine should not be used in patients with untreated hyperthyroidism. Fetal exposure to topiramate during the first trimester is associated with an increased risk of oral clefts.77 Female patients with child-bearing potential should be counseled on the risks of teratogenicity and consistent use of reliable contraception while using phentermine-topiramate ER.
Navigating the Role of Anti-Obesity Agents Prior to Pregnancy: A Narrative Review
2024, Seminars in Reproductive Medicine
This study was supported by cooperative agreement number U50/CCU113247 from the Centers for Disease Control and Prevention to the Slone Epidemiology Center through the Massachusetts Department of Public Health; cooperative agreements under PA 96043, PA 02081, and FOA DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study; and grant R01 HD 046595 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
The pharmacoepidemiology program at Harvard School of Public Health, which granted a student stipend to A.V.M., received funds for training grants for students from Pfizer and Asisa. A.A.M. owns Johnson & Johnson stock currently valued at less than $20,000. The North American AED Pregnancy Registry, to which S.H.-D. devotes less than 5% of her time, received grants from multiple pharmaceutical companies. A.A.M., M.M.W., R.J.G., and S.H.-D. have consulted for or received grants from pharmaceutical companies whose medications are not the subject of this analysis. S.M.G. and M.A.M. report no potential conflict of interest.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Cite this article as: Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:292.405.e1-7.